Last reviewed · How we verify

ONO-8025 (KRP-197) — Competitive Intelligence Brief

ONO-8025 (KRP-197) (ONO-8025 (KRP-197)) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostacyclin analog / IP receptor agonist. Area: Cardiovascular.

phase 3 Prostacyclin analog / IP receptor agonist Prostanoid IP receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ONO-8025 (KRP-197) (ONO-8025 (KRP-197)) — Ono Pharmaceutical Co. Ltd. ONO-8025 is a selective prostanoid receptor agonist that activates IP receptors to promote vasodilation and inhibit platelet aggregation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ONO-8025 (KRP-197) TARGET ONO-8025 (KRP-197) Ono Pharmaceutical Co. Ltd phase 3 Prostacyclin analog / IP receptor agonist Prostanoid IP receptor
ONO-5920 ONO-5920 Ono Pharmaceutical Co. Ltd phase 3 Prostanoid IP receptor agonist Prostanoid IP receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostacyclin analog / IP receptor agonist class)

  1. Ono Pharmaceutical Co. Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ONO-8025 (KRP-197) — Competitive Intelligence Brief. https://druglandscape.com/ci/ono-8025-krp-197. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: